Rosonabant

Rosonabant
Clinical data
ATC code	None;
Identifiers
	IUPAC name (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-piperidinyl)-4,5-dihydro-1H-pyrazole-3-carboxamide;
CAS Number	861151-12-4;
PubChemCID	11316914;
ChemSpider	9491881;
UNII	7X5RY2T485;
CompTox Dashboard(EPA)	DTXSID201006613;
Chemical and physical data
Formula	C21H21Cl3N4O
Molar mass	451.78g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NN1CCCCC1)\C4=N\N(c2ccc(Cl)cc2Cl)C(c3ccc(Cl)cc3)C4;
	InChI InChI=1S/C21H21Cl3N4O/c22-15-6-4-14(5-7-15)20-13-18(21(29)26-27-10-2-1-3-11-27)25-28(20)19-9-8-16(23)12-17(19)24/h4-9,12,20H,1-3,10-11,13H2,(H,26,29); Key:WMMMJGKFKKBRQR-UHFFFAOYSA-N;

Rosonabant(INN;E-6776) is adrugacting as aCB₁receptor antagonist/inverse agonistthat was under investigation byEsteveas anappetite suppressantfor the treatment ofobesity.^[1]^[2]Development of the drug forclinical usewas apparently halted shortly after the related CB₁antagonistrimonabantwas discontinued in November 2008,^[when?]due to the reports of severepsychiatric adverse effectssuch asanxiety,depression,andsuicidal ideationassociated with it and with similarly acting agents.^[3]^[4]^[5]

References[edit]

^Janero DR,Makriyannis A(March 2009). "Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis".Expert Opinion on Emerging Drugs.14(1): 43–65.doi:10.1517/14728210902736568.PMID 19249987.S2CID 74250986.
^Vickers SP, Cheetham SC (2007)."Preclinical Developments in Antiobesity Drugs".In Kirkham TC, Cooper SJ (eds.).Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs.Academic Press. p. 325.ISBN 978-0-12-370633-1.Retrieved12 May2012.
^Heal DJ, Gosden J, Smith SL (December 2009)."Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders".British Journal of Clinical Pharmacology.68(6): 861–874.doi:10.1111/j.1365-2125.2009.03549.x.PMC2810797.PMID 20002080.
^Lee HK, Choi EB, Pak CS (2009)."The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents".Current Topics in Medicinal Chemistry.9(6): 482–503.doi:10.2174/156802609788897844.PMID 19689362.Archived fromthe originalon 2013-05-22.
^Moreira FA, Crippa JA (June 2009)."The psychiatric side-effects of rimonabant".Revista Brasileira de Psiquiatria.31(2): 145–153.doi:10.1590/S1516-44462009000200012.PMID 19578688.

Thiscannabinoidrelated article is astub.You can help Wikipedia byexpanding it.